We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
6 own
17 watching
Current Price
$6.9
$-0.02
(-0.29%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
424.09M
52-Week High
18.25
52-Week Low
2.13
Average Volume
0.74M
Dividend Yield
--
P/E Ratio
--
Market Capitalization424.09M
52-Week High18.25
52-Week Low2.13
Average Volume0.74M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
MacroGenics, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The company's advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It also develops Enoblituzumab, a monoclonal antibody, which is in Phase 1 clinical trial as monotherapy in multiple solid tumor types, as well as in combination therapy with either an anti-PD-1 antibody or an anti-CTLA-4 antibody; Flotetuzumab, a DART molecule that targets CD123 and CD3; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Duvortuxizumab, a DART molecule that targets both CD19 and CD3; MGD009, a molecule in its B7-H3 franchise; MGA012, a monoclonal antibody, which targets PD-1; MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; and MGC018, a B7-H3 antibody-drug conjugate. In addition, the company's products include MGD010, a DART molecule designed to address limitations of existing B cell-targeted therapies by binding to the CD32B and CD79B proteins found on human B cells; Teplizumab, an anti-CD3 monoclonal antibody to treat type 1 diabetes; and MGD014, a DART molecule that targets human immunodeficiency virus, or HIV-infected cells, and CD3-expressing T cells. It has collaboration and license agreements with Janssen Biotech, Inc.; Les Laboratoires Servier and Institut de Recherches Servier; Boehringer Ingelheim GmbH; Pfizer, Inc.; and Green Cross Corp. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Market News Video
29days ago
In trading on Friday, shares of MacroGenics, Inc (MGNX) crossed above their 200 day moving average of 5.88, changing hands as high as 6.15 per share. MacroGenics, Inc shares are currently trading up about 22.9% on the day...
PR Newswire
1month ago
Thinking about buying stock in MacroGenics, Anavex Life Sciences, Uber Technologies, IVERIC bio, or Roblox? Thinking about buying stock in MacroGenics, Anavex Life Sciences, Uber Technologies, IVERIC bio, or Roblox? PR Newswire NEW YORK,, Oct. 17, 2022 NEW YORK,, Oct. 17, 2022 /PRNewswire...
Globe Newswire
3 months ago
ROCKVILLE, MD, Sept. 02, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the ...
Zolmax
5 months ago
Shares of MacroGenics, Inc. (NASDAQ:MGNX Get Rating) have received a consensus rating of Moderate Buy from the nine analysts that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and ...
Zolmax
6 months ago
Citigroup Inc. increased its stake in shares of MacroGenics, Inc. (NASDAQ:MGNX Get Rating) by 2.6% during the fourth quarter, Holdings Channel reports. The institutional investor owned 144,750 shares of the biopharmaceutical companys stock after acquiring an additional 3,628 shares during the period...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$6.9
$-0.02
(-0.29%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00